Results 181 to 190 of about 3,981,458 (213)
Some of the next articles are maybe not open access.
Management of Chemotherapy-Induced Thrombocytopenia: Current Status of Thrombopoietic Agents
Seminars in Hematology, 2009Myelosuppression, one of the most common toxicities of chemotherapy, results in varying degree of cytopenias. While neutropenia and anemia have been reduced with the currently approved hematopoietic growth factors, thrombocytopenia remains a significant clinical problem with an unmet medical need.
openaire +2 more sources
Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia
The Lancet Haematology, 2022Maria L, Lozano, Francesco, Rodeghiero
openaire +2 more sources
Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma
Journal of Oncology Pharmacy Practice, 2019Purpose Chemotherapy-induced thrombocytopenia is a serious complication in chemotherapy-treated patients. Identification of patients at risk for chemotherapy-induced thrombocytopenia could have clinical value in personalized management of patients and optimized administration of prophylactic thrombopoietic ...
Abolfazl Razzaghdoust +2 more
openaire +2 more sources
Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia
Seminars in Hematology, 2000Since the identification and cloning of c-Mpl ligand, two forms of recombinant human thrombopoietin have undergone clinical development. Both the full-length molecule, known as rhTPO, and the truncated version of the molecule, known as pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), have been evaluated in phase I ...
openaire +2 more sources
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011
Abnormal uterine bleeding in women with a blood dyscrasia, such as leukemia, or who experience thrombocytopenia secondary to myelosuppressive chemotherapy is a clinical condition associated with significant morbidity. Consequently, effective management is necessary to prevent adverse outcomes.
Jill S, Bates +2 more
openaire +2 more sources
Abnormal uterine bleeding in women with a blood dyscrasia, such as leukemia, or who experience thrombocytopenia secondary to myelosuppressive chemotherapy is a clinical condition associated with significant morbidity. Consequently, effective management is necessary to prevent adverse outcomes.
Jill S, Bates +2 more
openaire +2 more sources
Caring For The Patient With Chemotherapy-Induced Thrombocytopenia
AJN, American Journal of Nursing, 1981S S, Wroblewski, S H, Wroblewski
openaire +3 more sources
Impact of the Partial Splenic Embolization in the chemotherapy induced thrombocytopenia.
2018Aims and objectives: Splenic embolization is used to handle a myriad of diseases, such as splenic contusion, platelets sequestration, splenic artery aneurysmatic formations, increased portal vein pressure, and tumors of the spleen.
openaire +1 more source
Romiplostim management of chemotherapy-induced thrombocytopenia.
Journal of Clinical Oncology, 2016Gerald A. Soff +4 more
openaire +1 more source
TPO-mimetics for chemotherapy-induced thrombocytopenia: timing matters
Leukemia & Lymphoma, 2018Jerry, Soff, James, Bussel
openaire +2 more sources
Thrombopoietin-Receptor Agonists in Chemotherapy-Induced Thrombocytopenia
New England Journal of MedicineGeorge, Goshua, Alfred Ian, Lee
openaire +2 more sources